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Patients undergoing noncardiac surgery frequently
experience major adverse cardiac events. As a significant
proportion of these patients develop cardiac complications
despite optimal use of preoperative clinical risk-prediction
algorithms, physicians have long searched for better
methods of forecasting and ameliorating cardiac risk in this
population. Recently, postoperative troponin levels have
been found to be powerful and independent predictors of
cardiovascular mortality in patients undergoing noncardiac
surgery. Importantly, the predictive properties of these
markers outperform preoperative clinical risk-prediction
algorithms. We thus posit that the assessment of
postoperative troponin represents an as yet untapped
‘‘golden opportunity’’ for cardiac risk reduction. As cardiac
troponin isolates an unusually high-risk subgroup, we
outline a strategy that utilizes this marker to improve
cardiac outcomes. Where pertinent, strengths and
limitations of this approach are discussed and areas of
uncertainty identified. As with all hypotheses, this
proposition fuels many questions and calls for a research
agenda dedicated to quantifying risk or benefit, and
defining best practices. Journal of Hospital Medicine
2012;7:721–723.VC 2012 Society of Hospital Medicine
Noncardiac surgery is frequently associated with
major adverse cardiac events. Prevention of these
events has traditionally focused on risk estimation and
targeted interventions prior to surgical intervention.1
Cardiac risk is assessed through clinical prediction
rules, such as the revised cardiac risk index (RCRI) or
the American Society of Anesthesiology (ASA) classifi-
cation. In patients deemed to be at high risk of adverse
cardiac events, discretionary preoperative testing, medi-
cal treatments, and interventions are implemented.2
However, even when executed optimally, this approach
fails to protect all patients. Thus, many patients under-
going noncardiac surgery continue to experience peri-
operative myocardial infarction (MI) and death.3
Recently, a prospective international study involving
15,133 patients reported that cardiac troponin levels
measured within 3 days of noncardiac surgery were
strongly associated with 30-day mortality.4 This study
is but the latest in a series of investigations that have
concluded that postoperative measurement of cardiac
troponin is a better predictor of cardiac outcomes
than preoperative-risk algorithms.4–8 Intuitively, this
link is not surprising. Surgery represents the ultimate
physiologic stress test. In the setting of hemodynamic
changes and sustained oxygen supply:demand mismatch,
it is hardly shocking that those with significant epicardial
coronary stenosis or major subendocardial ischemia suf-
fer poorer outcomes. What is perhaps most important
about the association between troponin release and clini-
cal outcomes, however, is the foundation it provides for
a novel framework to improve perioperative care: using
troponin measurement to guide treatment and interven-
tions in the postoperative setting.
MODEL TO IMPROVE POSTOPERATIVE
CARDIAC OUTCOMES
We hypothesize that the postoperative period can be
seized as a ‘‘golden moment’’ to ameliorate cardiac
risk and improve clinical outcomes for 3 reasons.
First, those who release cardiac troponin during sur-
gery declare themselves as harboring myocardial terri-
tories in jeopardy. In effect, the peripheral presence of
troponin amounts to a cry for help in a population
where many cardiac events are silent and thus remain
clinically unnoticed.9,10 Routine postoperative moni-
toring for this biomarker can thus help identify a pop-
ulation that would ordinarily escape detection until
the precipitation of a major clinical event. Second, as
the pathophysiology of cardiac events centers around
rupture of vulnerable plaque (type-1 MI), supply:de-
mand mismatch (type-2 MI), or both of these phe-
nomena, escalation or institution of important medical
risk-reducing treatments (such as aspirin, beta-block-
ers, or statins), can be established to improve out-
comes. The ability to initiate these treatments in a
monitored setting may offset and address many of the
risks feared with these therapies, including hypoten-
sion, stroke, or rhabdomyolysis. Third, as patients
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convalesce from surgery, timely and discretionary car-
diac testing or interventions can be undertaken in those
identified as being at elevated cardiovascular risk prior
to discharge. In sum, the trifecta of clearly recognizing
those at risk, instituting interventions in controlled set-
tings, and performing well-timed interventions could
translate into greater odds of survival in this cohort.
Owing to their intimate involvement with patients
in the perioperative setting, hospitalists are uniquely
suited for implementing a troponin surveillance para-
digm. Yet, how may such a schema be realized? In
Figure 1, we outline a pathway with which to imple-
ment this approach. This model replicates periopera-
tive management workflow, calling for 3 discrete
interventions—preoperative assessment, perioperative
surveillance, and postoperative risk stratification:
1. Preoperative assessment: Patients estimated to be at
high risk of perioperative cardiac events (eg, RCRI 3)
should undergo baseline, preoperative high-sensitivity
troponin measurement, as the frequency of major
adverse cardiac outcomes is significant this group
(11%).11 The importance of a baseline measurement of
troponin cannot be overstated, as biologic variation of
this marker can impact subsequent management.12,13
Hospitalists can obtain these assays in preoperative clin-
ics at the time of initial review and risk-estimation.
2. Perioperative surveillance: Following the model imple-
mented by a recent study, serial troponin surveillance
should commence 6–12 hours after surgery, then daily
on the first, second, and third day.4 As the optimal car-
diac troponin threshold for the diagnosis of periopera-
tive ischemia remains uncertain, doubling of baseline
troponin levels may serve as a logical signal for further
evaluation.14 The electrocardiographic pattern may be
used as a branch point for immediate management at
this stage: ST-segment elevation MI may be treated
aggressively with an early invasive strategy and cardiac
catheterization when apropos (much as in the nonoper-
ative context). However, as most perioperative cardiac
events are non-ST elevation MIs, treatment of this sub-
set should center on initiation or escalation of medical
therapy. Thus, achieving heart-rate control in order to
preserve coronary perfusion by careful titration of beta-
blockers, and initiation/up-titration of statins to temper
unstable atherosclerotic plaques represent cornerstones
of this approach. Other potential therapeutic entities
such as initiation of angiotensin-converting-enzyme
(ACE)-inhibitors in the context of left-ventricular dys-
function, and/or antiplatelet agents such as aspirin,
may also be relevant risk-reducing tools.
3. Postoperative risk stratification: Prior to hospital dis-
charge, objective assessment of myocardial perfusion
and viability should occur in selected individuals with
troponin elevations. Modalities that may be utilized in
this context include either noninvasive imaging or occa-
sional coronary angiography in patients with unstable
FIG. 1. Suggested pathway for implementation of cardiac troponin to improve postoperative cardiac outcomes. Abbreviations: ACEi, angiotensin-converting-
enzyme inhibitors; hs-troponin; high-sensitivity troponin; MI, myocardial infarction; RCRI, revised cardiac risk index.
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coronary syndromes. Defining an optimal approach
must be contextual, as interventions that may subse-
quently mandate uninterrupted antiplatelet treatment
may be logistically challenging in this setting.
LIMITATIONS
Although this implementation model is plausible, it
generates many questions that must be tested through
the lens of a randomized controlled study. For
instance, what is the optimal strategy for intervention
in the postoperative setting? Though medical treat-
ment with statins and beta-blockade may represent
the mainstay of treatment, are these therapies safe
during potential clinical instability? Can net benefit be
realized through judicious use of coronary angiogra-
phy and revascularization? Can the artifact of height-
ened awareness and reporting of postoperative cardiac
events mar the reported quality of a hospital? Finally,
though cardiac troponin has been shown to be a
strong and independent predictor of mortality, which
troponin assay, reference range, and troponometric
standard to use remain unclear.15 Whether or not
these interventions translate into lesser mortality and
improved clinical outcomes represents the raison
d’etre for this experimental approach. As no alterna-
tive approach to define and target patients at high risk
of adverse outcome after seemingly ‘‘uneventful’’ sur-
gery currently exists, we believe that this hypothetical
paradigm is worthy of further investigation.
CONCLUSION
For decades, perioperative practitioners have searched
for a divining rod to reduce risk during surgery. While
our efforts have been focused on the preoperative set-
ting, the postoperative setting represents an as yet
untapped and potentially profound period in the quest
to improving surgical outcomes. Through our proxim-
ity to patients in the perioperative setting, hospitalists
are ideal agents to test, deliver, and bring about this
change. It is time for a postoperative carpe diem.
Disclosure: Nothing to report.
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